Joel Isaacson & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Joel Isaacson & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-480	Closed	-$59K	–	578
2016 Q4	$59K	Hold	480	–	–	0.01%	282
2016 Q3	$59K	Hold	480	–	–	0.01%	301
2016 Q2	$56K	Sell	480 -150	-24%	-$21.3K	0.01%	309
2016 Q1	$88K	Hold	630	–	–	0.02%	254
2015 Q4	$120K	Hold	630	–	–	0.03%	205
2015 Q3	$99K	Hold	630	–	–	0.03%	230
2015 Q2	$114K	Hold	630	–	–	0.03%	236
2015 Q1	$109K	Hold	630	–	–	0.03%	244
2014 Q4	$117K	Hold	630	–	–	0.03%	214
2014 Q3	$104K	Buy	630 +150	+31%	+$24.6K	0.03%	202
2014 Q2	$75K	Hold	480	–	–	0.02%	248
2014 Q1	$73K	Hold	480	–	–	0.02%	243
2013 Q4	$64K	Hold	480	–	–	0.02%	240
2013 Q3	$56K	Buy	480 +300	+167%	+$32.9K	0.02%	242
2013 Q2	$17K	Buy	+180	New	+$17.3K	0.01%	347

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Joel Isaacson & Co's ALXN Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 480 shares — an estimated $59K sold.

Joel Isaacson & Co first reported a position in ALXN in Q2 2013 and held it in 15 quarters. The position peaked at $120K in Q4 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

Joel Isaacson & Co reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 480 Alexion Pharmaceuticals shares in Q1 2017, an estimated $59K.
Joel Isaacson & Co first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Joel Isaacson & Co's Alexion Pharmaceuticals position peaked at $120K in Q4 2015.
561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.